Wendy Wong, MD
Family Medicine · Silver Spring, MDNPI 1184600801
Payments from drug & device makers
Across 258 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$809
- AbbVie$708
- Novo Nordisk$685
- Amgen$611
- Pfizer$497
- Gilead$290
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,205100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 42 | $809 |
| AbbVie(2 entities) | 45 | $708 |
| Novo Nordisk | 32 | $685 |
| Amgen(2 entities) | 29 | $611 |
| Pfizer | 20 | $497 |
| Gilead | 4 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $196 |
| Biohaven Pharmaceuticals, Inc. | 13 | $190 |
| GSK | 9 | $182 |
| Exact Sciences | 9 | $176 |
| Abbott | 3 | $127 |
| AstraZeneca | 6 | $108 |
| Idorsia Pharmaceuticals US Inc | 1 | $105 |
| Boehringer Ingelheim | 2 | $56 |
| Novartis | 4 | $53 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $51 |
| Amarin Pharma, Inc. | 3 | $35 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Merck | 2 | $25 |
| Cumberland Pharmaceuticals, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Bayer | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,212 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 44 | $51,904 |
| OzempicSemaglutide | 15 | $36,053 |
| EliquisApixaban | 32 | $29,631 |
| JardianceEmpagliflozin | 15 | $25,025 |
| LinzessLinaclotide | 19 | $11,621 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,184 |
| Repatha SureclickEvolocumab | 14 | $8,836 |
| XareltoRivaroxaban | 13 | $7,402 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,914 |
| Atorvastatin Calcium | 525 | $5,655 |
| Levothyroxine Sodium | 333 | $4,035 |
| Metoprolol Succinate | 215 | $3,704 |
| Amlodipine-AtorvastatinAmlodipine/Atorvastatin | 16 | $3,630 |
| Diclofenac Sodium | 42 | $3,242 |
| Amlodipine Besylate | 394 | $3,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $25 | $51,90444 claims |
| Novo NordiskOzempic | $685 | $36,05315 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $56 | $34,20832 claims |
| PfizerEliquis, Paxlovid | $497 | $31,06054 claims |
| AbbVieLinzess, Synthroid | $708 | $13,08554 claims |
| Johnson & JohnsonXarelto | $14 | $7,40213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $196 | $5,91412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $4,035333 claims |
| AstraZenecaSymbicort | $108 | $2,56212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Silver Spring
- Cynthia KleppingerSilver Spring$51K
- Jean WelshSilver Spring$26K
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.